Drug intelligence / Profile preview

ASC930

Development stage: Phase 2
Lead developer: ASC Therapeutics
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

ASC930 is a cell therapy consisting of placenta-derived decidual stromal cells (DSCs) isolated from the fetal membrane of maternal origin. Developed by ASC Therapeutics, these stromal cells possess potent immunosuppressive and immunomodulatory properties, making them a candidate for treating immune-triggered conditions like acute Graft-versus-Host Disease (aGVHD). In aGVHD, ASC930 is intended to reduce profound immune dysregulation and organ dysfunction by modulating T-cell activity and inflammatory cytokine production. The therapy is administered intravenously and is currently being evaluated in patients with steroid-refractory acute Graft-versus-Host Disease.

Other names: Placenta-derived decidual stromal cellsDSCsasc-930asc930asc 930

Beyond the preview

Go deeper on ASC930.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASC930.

Explore the full profile